Logan Capital Management Inc. Decreases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Logan Capital Management Inc. decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 23,730 shares of the medical research company’s stock after selling 275 shares during the period. Logan Capital Management Inc.’s holdings in Charles River Laboratories International were worth $4,674,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. State Street Corp raised its holdings in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its position in Charles River Laboratories International by 1.7% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after acquiring an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the period. Finally, Earnest Partners LLC grew its position in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after acquiring an additional 110,725 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Evercore ISI boosted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Redburn Atlantic initiated coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, Robert W. Baird dropped their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Stock Down 2.0 %

Charles River Laboratories International stock opened at $190.45 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The company has a 50-day simple moving average of $194.35 and a 200-day simple moving average of $203.10. The firm has a market capitalization of $9.74 billion, a P/E ratio of 23.84, a P/E/G ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $2.72 earnings per share. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).